Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Stock Has Average Target Price of $53.33 According to Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received an average rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $53.33.

Separately, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th.

Reviva Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:RVPH opened at $0.47 on Monday. Reviva Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $17.20. The stock’s fifty day simple moving average is $0.49 and its 200-day simple moving average is $0.65. The company has a market capitalization of $6.16 million, a P/E ratio of -0.25 and a beta of 0.50.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19. On average, sell-side analysts anticipate that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s research is based on its proprietary drug-discovery platform, which is designed to identify medicines that act on multiple serotonin and dopamine receptors.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational multimodal serotonin-dopamine activity modulator being developed for schizophrenia and other neuropsychiatric and inflammatory conditions, including bipolar depression, major depressive disorder, and certain dementia-related psychoses.